In:
Cancer, Wiley, Vol. 125, No. 17 ( 2019-09), p. 3001-3012
Abstract:
In the current study, 62 patients with newly diagnosed acute promyelocytic leukemia are treated with oral arsenic trioxide, all‐trans retinoic acid, and ascorbic acid as part of their induction regimen, with all achieving complete remission, and this is followed by consolidation with daunorubicin and cytarabine and maintenance with oral arsenic trioxide, all‐trans retinoic acid, and ascorbic acid. In comparison with a contemporaneous cohort of 37 patients with newly diagnosed acute promyelocytic leukemia who are treated similarly but without oral arsenic trioxide during induction, the oral arsenic trioxide cohort appears to have significantly superior leukemia‐free survival.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v125.17
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink